Sigrid Therapeutics has been granted a US patent for its SiPore® platform — a silica-based technology designed to lower blood glucose levels.
SiPore can also reduce the risk of developing type II diabetes, metabolic syndrome, insulin resistance and other obesity-related complications.
The US Patent Office (USPTO) has granted Sigrid with a patent entitled: "Porous silica material for use as a pharmaceutical or dietary active ingredient".
Therefore, Sigrid Therapeutics is the only company that can produce mesoporous, micron-sized silica particles designed to lower blood glucose levels.
"The granting of this patent significantly strengthens Sigrid’s global IP portfolio and highlights the versatility of our SiPore technology in addressing critical metabolic health challenges," said Ghislaine Robert-Nicoud, Head of Product Development at Sigrid Therapeutics.
"The recognition of our product’s potential by the USPTO further validates our expertise in developing silica-based biomaterials for managing blood glucose. This milestone enhances the commercial appeal of SiPore in one of the most important global markets."
"This comes as we finalise our SHINE clinical trial in people with elevated blood glucose levels who are living with obesity or excess weight, with results expected in the first quarter of 2025."
SiPore 21
The company's lead product candidate, SiPore 21, is an orally-administered, Class IIB medical device (as per EU guidelines) that is considered a medical food in the US.
Sipore 21 is a gel that can be consumed alongside a meal, and acts locally in the gut to promote effective blood sugar management without the body absorbing it.
CEO and co-founder of Sigrid Therapeutics, Sana Alajmovic, commented: “Our vision with SiPore21 is to transform blood sugar control by delivering an accessible and effective solution that enables millions of individuals worldwide to take charge of their metabolic health."
"This new patent further solidifies our competitive edge as we advance discussions with leading global consumer healthcare companies and top-performing regional distributors, who have shown strong interest in partnering with us upon achieving regulatory approvals.”
In 2021, the European Patent Office (EPO) similarly granted the company patent EP2916852B1 for the use of porous SiPore silica particles as pharmaceutical or dietary active ingredients.
The European patent is validated in key markets including the EU, UK, Switzerland, Norway, Iceland and Turkey.